Zomagen Biosciences Ltd.
Clinical trials sponsored by Zomagen Biosciences Ltd., explained in plain language.
-
New obesity drug combo tested for safety
Disease control CompletedThis study tested whether a new drug called VTX3232, taken alone or with semaglutide, is safe for people with obesity. About 176 adults with a BMI between 30 and 42 took part. The study lasted 12 weeks and checked for side effects and changes in inflammation levels.
Phase: PHASE2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug VTX3232 tested for safety in early Parkinson's patients
Symptom relief CompletedThis study tested whether a drug called VTX3232 is safe for people with early-stage Parkinson's disease. Eleven participants took the drug for 28 days and were monitored for side effects. The goal was to check safety and how the drug moves through the body, not to cure the diseas…
Phase: PHASE2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Symptom relief
Last updated May 26, 2026 09:08 UTC